Terms: = Thyroid cancer AND ER, estrogen receptor
827 results:
1. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract] [Full Text] [Related]
2. Columnar Cell thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary thyroid Carcinoma and Follicular Neoplasms.
Higgins KE; Sadow PM; Johnson DN; Wang P; Wanjari P; Cipriani NA
Head Neck Pathol; 2024 May; 18(1):39. PubMed ID: 38727854
[TBL] [Abstract] [Full Text] [Related]
3.
Zang Z; Yin Y; Liu C; Zhu Q; Huang X; Li H; Yang R
Epigenetics; 2024 Dec; 19(1):2352683. PubMed ID: 38723244
[TBL] [Abstract] [Full Text] [Related]
4. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
5. [Non-primary solid malignancies of breast in needle core biopsy: a clinicopathological analysis of 23 cases].
Gu WQ; Wang L; Xu JC; Ping GQ; Han X; Wang C
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):331-336. PubMed ID: 38556815
[No Abstract] [Full Text] [Related]
6. Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas.
Momeni-Boroujeni A; Mullaney K; DiNapoli SE; Leitao MM; Hensley ML; Katabi N; Allison DHR; Park KJ; Antonescu CR; Chiang S
Mod Pathol; 2024 May; 37(5):100474. PubMed ID: 38508521
[TBL] [Abstract] [Full Text] [Related]
7. Application of fluorocarbon nanoparticles of
Zhi L; Cheng C; Jing L; Zhi-Ping P; Lu Y; Yan T; Zhi-Gang W; Guo-Bing Y
J Nanobiotechnology; 2024 Mar; 22(1):107. PubMed ID: 38475902
[TBL] [Abstract] [Full Text] [Related]
8. The exposure to UV filters: Prevalence, effects, possible molecular mechanisms of action and interactions within mixtures.
Rafeletou A; Niemi JVL; Lagunas-Rangel FA; Liu W; Kudłak B; Schiöth HB
Sci Total Environ; 2024 Jun; 928():170999. PubMed ID: 38458461
[TBL] [Abstract] [Full Text] [Related]
9. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
10. A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis.
Yang T; Li W; Zhou J; Xu M; Huang Z; Ming J; Huang T
Cell Death Dis; 2024 Feb; 15(2):147. PubMed ID: 38360722
[TBL] [Abstract] [Full Text] [Related]
11. HNRNPC promotes estrogen receptor-positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A-dependent manner.
Xu W; Huang Z; Xiao Y; Li W; Xu M; Zhao Q; Yi P
Mol Carcinog; 2024 May; 63(5):859-873. PubMed ID: 38353359
[TBL] [Abstract] [Full Text] [Related]
12. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
13. Effects of postoperative antioxidants on the salivary glands in patients with thyroid cancer undergoing radioactive iodine-131 treatment.
Tong H; Yue R; Fang J; Li X; Yang S; Hou Y; Wang R; Zhang B; Liu H; Wu Z; Cheng Y
Nucl Med Commun; 2024 Apr; 45(4):312-320. PubMed ID: 38312062
[TBL] [Abstract] [Full Text] [Related]
14. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract] [Full Text] [Related]
15. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
16. Expression Significance of estrogen receptor ER-α36 in Breast cancer Treated by Chemotherapy: A Meta-Analysis.
He E; Xia X; Quan H; Leng P
Mol Biotechnol; 2024 May; 66(5):991-999. PubMed ID: 38270756
[TBL] [Abstract] [Full Text] [Related]
17. 2020 Annual Report of National Clinical Database-Breast cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Sagara Y; Kumamaru H; Niikura N; Miyashita M; Konishi T; Iwamoto T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Kinukawa N; Watanabe C; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):179-184. PubMed ID: 38180641
[TBL] [Abstract] [Full Text] [Related]
18. USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis.
Gao S; Wang Y; Xu Y; Liu L; Liu S
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167011. PubMed ID: 38176460
[TBL] [Abstract] [Full Text] [Related]
19. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract] [Full Text] [Related]
20. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract] [Full Text] [Related]
[Next]